Screener
Axsome Therapeutics AXSM Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Proceeds from draw down of debt | 70,000 | — |
| Repayment of debt | (70,000) | — |
| Payments on principal portion of finance lease obligation | (672) | (401) |
| Proceeds from issuance of common stock upon financing | 6,343 | 19,650 |
| Cash paid for common stock issuance costs | (95) | (393) |
| Proceeds from issuance of common stock upon exercise of options | 9,981 | 17,035 |
| Payment of contingent consideration | (3,262) | (2,285) |
| Payments of tax withholdings on stock awards | (9,301) | (4,336) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's stock issuance proceeds?
- Axsome Therapeutics (AXSM) reported stock issuance proceeds of $6.34M in Q1 2026.
- How has Axsome Therapeutics's stock issuance proceeds changed year-over-year?
- Axsome Therapeutics's stock issuance proceeds decreased by 67.7% year-over-year, from $19.65M to $6.34M.
- What is the long-term trend for Axsome Therapeutics's stock issuance proceeds?
- Over 4 years (2021 to 2025), Axsome Therapeutics's stock issuance proceeds has grown at a 73.8% compound annual growth rate (CAGR), from $7.44M to $67.9M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about Axsome Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude